Novavax Inc (NVAX) 11.99 $NVAX
Novavax Up 34.2% Since SmarTrend Uptrend Call (NVAX)
Comtex SmarTrend(R) - Tue Jul 21, 10:35AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on June 18th, 2015 at $9.35. In approximately 1 month, Novavax has returned 34.22% as of today's recent price of $12.55.
NVAX: 11.99 (-0.43)
Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference
GlobeNewswire - Tue Jul 21, 7:30AM CDT
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M(TM) as part of the World Health Organization's (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax' proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.
NVAX: 11.99 (-0.43)
Updates on Biotechnology Industry Stocks -- ZIOPHARM Oncology, Novavax, Galena Biopharma, Sorrento Therapeutics, and Aegerion Pharma
PR Newswire - Fri Jul 17, 8:25AM CDT
Equity Research Institute has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Novavax Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Sorrento Therapeutics Inc. (NASDAQ: SRNE), and Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR). Free research report on ZIOPHARM Oncology can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ZIOP On Thursday, July 16, 2015, the NASDAQ Composite ended at 5,163.18, up 1.26%, the Dow Jones Industrial Average advanced 0.39%, to finish the day at 18,120.25, and the S&P 500 closed at 2,124.29, up 0.80%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
ZIOP: 12.59 (-0.19), NVAX: 11.99 (-0.43), AEGR: 18.29 (-0.34), GALE: 1.67 (-0.03), SRNE: 24.31 (-0.05)
Novavax Has Returned 28.4% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Tue Jul 14, 9:19AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on June 18th, 2015 at $9.35. In approximately 4 weeks, Novavax has returned 28.36% as of today's recent price of $12.00.
NVAX: 11.99 (-0.43)
The Single Greatest Mistake You Can Make When Investing in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sun Jul 12, 1:02PM CDT
Source: Food and Drug Administration via Facebook Investing in the biotech sector since the Great Recession must be somewhat reminiscent of the pre-dot-com bubble for traders. These days it seems as if you threw a dart at the newspaper you could...
NVAX: 11.99 (-0.43), TKMR: 10.73 (+0.39)
Novavax (NVAX) Looks Good: Stock Moves 11% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 10, 8:46AM CDT
Novavax (NVAX) was a big mover last session, with shares rising 11% on the day.
NVAX: 11.99 (-0.43), AMAG: 71.31 (-1.23)
'Mad Money' Lightning Round: Sell, Sell, Sell Dillard's, It's Overdone
at The Street - Fri Jul 10, 5:00AM CDT
Cramer prefers Waste Management over Progressive Waste Solutions and is going to wait before pulling the trigger on Boeing.
DDS: 100.39 (-2.32), NVAX: 11.99 (-0.43), BIN: 24.70 (-0.07), TKR: 32.66 (-0.56), RIO: 38.53 (-0.50), BA: 146.11 (-0.36), WM: 49.08 (+1.28), MA: 95.16 (-1.72)
Jim Cramer's 'Mad Money' Recap: Timing Is Everything in Buying Stocks
at The Street - Thu Jul 09, 7:23PM CDT
You should've been selling this morning and buying in the afternoon, Cramer says. Here's why.
MDLZ: 42.12 (-0.13), EA: 71.81 (-1.11), AAP: 168.39 (+0.17), HON: 104.32 (-0.42), NKE: 114.00 (-0.09), SNA: 162.07 (-0.06), UPS: 96.11 (-1.12), PEP: 96.87 (-0.30), SWK: 106.35 (-0.34), NVAX: 11.99 (-0.43), TMUS: 37.93 (+0.20), RIO: 38.53 (-0.50), MA: 95.16 (-1.72), ORLY: 240.67 (+0.02), DIS: 118.80 (-0.53), STZ: 117.56 (-1.81), LLY: 86.76 (+0.38), TKR: 32.66 (-0.56), BA: 146.11 (-0.36), WM: 49.08 (+1.28), DDS: 100.39 (-2.32), WBA: 95.48 (-1.16), MPC: 56.33 (-0.74), MHK: 197.99 (+0.17), KHC: 76.74 (-1.90), BIN: 24.70 (-0.07), BEAV: 48.34 (+0.86), ULTA: 169.22 (-1.30), GIS: 57.08 (-0.55), CMCSA: 62.47 (-2.03)
After Yesterday's Rally of 11.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 09, 4:26PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $11.26 to a high of $12.17. Yesterday, the shares gained 11.0%, which took the trading range above the 3-day high of $11.36 on volume of 7.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 11.99 (-0.43)
Ebola Viral Infections Therapeutics Pipeline Review, H1 2015 - 30 Companies & 61 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdd37g/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Canopus BioPharma Incorporated - Crucell N.V. - Etubics Corporation - FIT Biotech Oy - GeoVax Labs, Inc. - GlaxoSmithKline plc - Hemispherx Biopharma, Inc. - Humabs BioMed SA - Immune Response BioPharma, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Kymab Limited - Medicago Inc. - Merck & Co., Inc. - Microbiotix, Inc. - Navigen Pharmaceuticals, Inc. - Novavax, Inc. - Peregrine Pharmaceuticals, Inc. - SignPath Pharma Inc - Sihuan Pharmaceutical Holdings Group Ltd. - SKAU Vaccines ApS - Tamir Biotechnology, Inc. - Tekmira Pharmaceuticals Corp. - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxart, Inc. - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/qd...bola_viral
UTHR: 175.10 (+0.50), TKMR: 10.73 (+0.39), GSK: 42.00 (-0.30), INO: 7.23 (-0.09), NVAX: 11.99 (-0.43), MRK: 58.07 (-0.06)
Why Novavax Shares Rocketed Higher By Nearly 25% in June
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 07, 12:02PM CDT
What: Shares of Novavax , a clinical-stage biopharmaceutical company focused on the development of vaccines to treat a variety of infectious diseases, surged by 24% in June, based on data from S&P Capital IQ , due to infectious disease...
NVAX: 11.99 (-0.43)
Weighing The Week Ahead: Will Fedspeak Interrupt The Lazy-Hazy-Crazy Days Of Summer?
Jeff Miller - Seeking Alpha - Sun Jul 05, 1:30AM CDT
In one sense, the week ahead should be a quiet, dull semi-vacation. As Nat King Cole explained , the Lazy-Hazy-Crazy days of summer - pretzels, beer, and bikinis that never got wet. It is the lull before earnings and includes a light economic...
HOG: 58.25 (-0.36), ZIOP: 12.59 (-0.19), SPY: 210.18 (-1.19), QQQ: 112.20 (-0.42), GREK: 10.05 (-0.02), NVAX: 11.99 (-0.43), DIA: 177.16 (-1.14)
How To Make Money In Small To Nano-Cap Biotech
Scrying Biotech - at Seeking Alpha - Wed Jun 24, 12:55PM CDT
SGYP: 8.42 (-0.14), TRVN: 6.80 (-0.04), OCAT: 4.84 (-0.05), MNOV: 3.70 (+0.02), SGEN: 50.81 (-0.21), NVAX: 11.99 (-0.43), NKTR: 12.72 (-0.07)
Strength Seen in Novavax (NVAX): Stock Gains 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 24, 8:46AM CDT
Novavax (NVAX) was a big mover last session, with shares rising roughly 12% on the day.
CBM: 49.61 (-0.33), NVAX: 11.99 (-0.43)
Can The Uptrend Continue for Novavax (NVAX)?
Novavax Up 34.2% Since SmarTrend Uptrend Call (NVAX)
Comtex SmarTrend(R) - Tue Jul 21, 10:35AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on June 18th, 2015 at $9.35. In approximately 1 month, Novavax has returned 34.22% as of today's recent price of $12.55.
NVAX: 11.99 (-0.43)
Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference
GlobeNewswire - Tue Jul 21, 7:30AM CDT
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M(TM) as part of the World Health Organization's (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax' proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.
NVAX: 11.99 (-0.43)
Updates on Biotechnology Industry Stocks -- ZIOPHARM Oncology, Novavax, Galena Biopharma, Sorrento Therapeutics, and Aegerion Pharma
PR Newswire - Fri Jul 17, 8:25AM CDT
Equity Research Institute has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Novavax Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Sorrento Therapeutics Inc. (NASDAQ: SRNE), and Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR). Free research report on ZIOPHARM Oncology can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ZIOP On Thursday, July 16, 2015, the NASDAQ Composite ended at 5,163.18, up 1.26%, the Dow Jones Industrial Average advanced 0.39%, to finish the day at 18,120.25, and the S&P 500 closed at 2,124.29, up 0.80%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
ZIOP: 12.59 (-0.19), NVAX: 11.99 (-0.43), AEGR: 18.29 (-0.34), GALE: 1.67 (-0.03), SRNE: 24.31 (-0.05)
Novavax Has Returned 28.4% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Tue Jul 14, 9:19AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on June 18th, 2015 at $9.35. In approximately 4 weeks, Novavax has returned 28.36% as of today's recent price of $12.00.
NVAX: 11.99 (-0.43)
The Single Greatest Mistake You Can Make When Investing in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sun Jul 12, 1:02PM CDT
Source: Food and Drug Administration via Facebook Investing in the biotech sector since the Great Recession must be somewhat reminiscent of the pre-dot-com bubble for traders. These days it seems as if you threw a dart at the newspaper you could...
NVAX: 11.99 (-0.43), TKMR: 10.73 (+0.39)
Novavax (NVAX) Looks Good: Stock Moves 11% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 10, 8:46AM CDT
Novavax (NVAX) was a big mover last session, with shares rising 11% on the day.
NVAX: 11.99 (-0.43), AMAG: 71.31 (-1.23)
'Mad Money' Lightning Round: Sell, Sell, Sell Dillard's, It's Overdone
at The Street - Fri Jul 10, 5:00AM CDT
Cramer prefers Waste Management over Progressive Waste Solutions and is going to wait before pulling the trigger on Boeing.
DDS: 100.39 (-2.32), NVAX: 11.99 (-0.43), BIN: 24.70 (-0.07), TKR: 32.66 (-0.56), RIO: 38.53 (-0.50), BA: 146.11 (-0.36), WM: 49.08 (+1.28), MA: 95.16 (-1.72)
Jim Cramer's 'Mad Money' Recap: Timing Is Everything in Buying Stocks
at The Street - Thu Jul 09, 7:23PM CDT
You should've been selling this morning and buying in the afternoon, Cramer says. Here's why.
MDLZ: 42.12 (-0.13), EA: 71.81 (-1.11), AAP: 168.39 (+0.17), HON: 104.32 (-0.42), NKE: 114.00 (-0.09), SNA: 162.07 (-0.06), UPS: 96.11 (-1.12), PEP: 96.87 (-0.30), SWK: 106.35 (-0.34), NVAX: 11.99 (-0.43), TMUS: 37.93 (+0.20), RIO: 38.53 (-0.50), MA: 95.16 (-1.72), ORLY: 240.67 (+0.02), DIS: 118.80 (-0.53), STZ: 117.56 (-1.81), LLY: 86.76 (+0.38), TKR: 32.66 (-0.56), BA: 146.11 (-0.36), WM: 49.08 (+1.28), DDS: 100.39 (-2.32), WBA: 95.48 (-1.16), MPC: 56.33 (-0.74), MHK: 197.99 (+0.17), KHC: 76.74 (-1.90), BIN: 24.70 (-0.07), BEAV: 48.34 (+0.86), ULTA: 169.22 (-1.30), GIS: 57.08 (-0.55), CMCSA: 62.47 (-2.03)
After Yesterday's Rally of 11.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 09, 4:26PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $11.26 to a high of $12.17. Yesterday, the shares gained 11.0%, which took the trading range above the 3-day high of $11.36 on volume of 7.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 11.99 (-0.43)
Ebola Viral Infections Therapeutics Pipeline Review, H1 2015 - 30 Companies & 61 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdd37g/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Canopus BioPharma Incorporated - Crucell N.V. - Etubics Corporation - FIT Biotech Oy - GeoVax Labs, Inc. - GlaxoSmithKline plc - Hemispherx Biopharma, Inc. - Humabs BioMed SA - Immune Response BioPharma, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Kymab Limited - Medicago Inc. - Merck & Co., Inc. - Microbiotix, Inc. - Navigen Pharmaceuticals, Inc. - Novavax, Inc. - Peregrine Pharmaceuticals, Inc. - SignPath Pharma Inc - Sihuan Pharmaceutical Holdings Group Ltd. - SKAU Vaccines ApS - Tamir Biotechnology, Inc. - Tekmira Pharmaceuticals Corp. - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxart, Inc. - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/qd...bola_viral
UTHR: 175.10 (+0.50), TKMR: 10.73 (+0.39), GSK: 42.00 (-0.30), INO: 7.23 (-0.09), NVAX: 11.99 (-0.43), MRK: 58.07 (-0.06)
Why Novavax Shares Rocketed Higher By Nearly 25% in June
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 07, 12:02PM CDT
What: Shares of Novavax , a clinical-stage biopharmaceutical company focused on the development of vaccines to treat a variety of infectious diseases, surged by 24% in June, based on data from S&P Capital IQ , due to infectious disease...
NVAX: 11.99 (-0.43)
Weighing The Week Ahead: Will Fedspeak Interrupt The Lazy-Hazy-Crazy Days Of Summer?
Jeff Miller - Seeking Alpha - Sun Jul 05, 1:30AM CDT
In one sense, the week ahead should be a quiet, dull semi-vacation. As Nat King Cole explained , the Lazy-Hazy-Crazy days of summer - pretzels, beer, and bikinis that never got wet. It is the lull before earnings and includes a light economic...
HOG: 58.25 (-0.36), ZIOP: 12.59 (-0.19), SPY: 210.18 (-1.19), QQQ: 112.20 (-0.42), GREK: 10.05 (-0.02), NVAX: 11.99 (-0.43), DIA: 177.16 (-1.14)
How To Make Money In Small To Nano-Cap Biotech
Scrying Biotech - at Seeking Alpha - Wed Jun 24, 12:55PM CDT
SGYP: 8.42 (-0.14), TRVN: 6.80 (-0.04), OCAT: 4.84 (-0.05), MNOV: 3.70 (+0.02), SGEN: 50.81 (-0.21), NVAX: 11.99 (-0.43), NKTR: 12.72 (-0.07)
Strength Seen in Novavax (NVAX): Stock Gains 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 24, 8:46AM CDT
Novavax (NVAX) was a big mover last session, with shares rising roughly 12% on the day.
CBM: 49.61 (-0.33), NVAX: 11.99 (-0.43)
Can The Uptrend Continue for Novavax (NVAX)?
